Restora Medical files Form D for $15M private placement, raises $11.5M
What's the deal? Restora Medical, Inc. has filed a Form D with the US Securities and Exchange Commission disclosing a $15M private placement offering. The Irvine, California-based medical device startup has sold $11.5M of the offering to five accredited investors, with $3.5M still on the table.
Founded in 2023 and operating in stealth, Restora Medical is developing an investigational medical device under US FDA regulations. The board includes Chau Khuong (Private Equity Partner at OrbiMed) and medtech serial entrepreneur Lixiao Wang , with Quan Ni serving as executive officer.
Why it matters. The May 2026 filing follows two earlier Form D filings (January 2024 and March 2025), suggesting Restora has been quietly building capital across multiple tranches since launch. The presence of OrbiMed on the cap table — one of the most active healthcare specialist investors — combined with Lixiao Wang's track record (multiple successful medical-device exits) signals a serious bet on whatever device platform the company is incubating.
The signal. US medtech continues to draw private capital despite a selective broader venture market. Stealth-mode device companies with veteran founders and tier-1 healthcare specialists are increasingly funded through staged private placements rather than splashy Series rounds — making SEC filings the only public window into early medtech activity.
Read more: ainvest.com
